13 studies found for:    PA-21
Show Display Options
Rank Status Study
1 Completed A Drug-Drug Interaction Study of Omeprazole and PA21
Condition: Healthy
Interventions: Drug: PA21 and Omeprazole with food;   Drug: No PA21; Omeprazole with food;   Drug: PA21 with food, Omeprazole 2hrs later
2 Completed A Drug-Drug Interaction Study of Furosemide and PA21
Condition: Healthy
Interventions: Drug: PA21 and Furosemide with food;   Drug: No PA21; Furosemide with food;   Drug: PA21 with food and Furosemide 2hrs later
3 Completed A Drug-Drug Interaction Study of Losartan and PA21
Condition: Drug Interaction Potentiation
Interventions: Drug: PA21 and Losartan with Food;   Drug: No PA21; Losartan with food;   Drug: PA21 with food and Losartan 2 hours later
4 Completed
Has Results
Study of Phosphate Levels in Patients With Chronic Kidney Disease
Condition: Chronic Kidney Disease
Interventions: Drug: 1.25 g PA21 (250 mg iron);   Drug: 5.0 g PA21 (1,000 mg iron);   Drug: 7.5 g PA21 (1,500 mg iron);   Drug: 10.0 g PA21 (2,000 mg iron);   Drug: 12.5 g PA21 (2,500 mg iron);   Drug: Sevelamer hydrochloride
5 Completed
Has Results
A Phase 3 Study to Investigate the Safety and Efficacy of PA21, a Phosphate Binder, in Dialysis Patients
Condition: Chronic Kidney Disease Requiring Chronic Dialysis
Interventions: Drug: PA21 (2.5 g tablet containing 500 mg iron);   Drug: Sevelamer carbonate;   Drug: PA21-1 (1.25 g tablet containing 250 mg iron)
6 Completed PA21 Phase II Clinical Study in Hemodialysis Patients With Hyperphosphatemia
Condition: Chronic Kidney Disease Requiring Hemodialysis
Interventions: Drug: PA21;   Drug: Placebo
7 Completed A Drug-Drug Interaction Study of Warfarin and PA21
Condition: Drug Interaction Potentiation
Interventions: Drug: PA21;   Drug: Warfarin
8 Completed A Drug-Drug Interaction Study of Digoxin and PA21
Condition: Drug Interaction Potentiation
Interventions: Drug: PA21;   Drug: Digoxin
9 Completed
Has Results
A Phase 3 Extension Study to Investigate the Long-term Safety, Tolerability and Efficacy of PA21, a Phosphate Binder in Dialysis Patients
Condition: Chronic Kidney Disease Requiring Chronic Dialysis
Interventions: Drug: PA21 (2.5 g tablet containing 500 mg iron);   Drug: Sevelamer carbonate
10 Active, not recruiting A Long-term Study of PA21 in Hemodialysis Patients With Hyperphosphatemia
Condition: Hemodialysis Patients With Hyperphosphatemia
Intervention: Drug: PA21
11 Active, not recruiting A Phase III Study of PA21 in Hemodialysis Patients With Hyperphosphatemia
Conditions: Hemodialysis;   Hyperphosphatemia
Interventions: Drug: PA21;   Drug: Sevelamer hydrochloride
12 Active, not recruiting A Phase III Study of PA21 in Peritoneal Dialysis Patients With Hyperphosphatemia
Conditions: Peritoneal Dialysis;   Hyperphosphatemia
Intervention: Drug: PA21
13 Active, not recruiting A Phase III Study of PA21 With Calcium Carbonate in Hemodialysis Patients With Hyperphosphatemia
Conditions: Hemodialysis;   Hyperphosphatemia
Intervention: Drug: PA21

Indicates status has not been verified in more than two years